All news

Pic:getty/stanislawpytel

Emmes launches cell and gene therapy center

By Rachel Arthur

Emmes has announced the creation of a dedicated center for cell and gene therapy research: which will focus on supporting clinical trials for the Clinical Research Organization’s (CRO) clients.

© GettyImages/Frank Brennan

ADDF: Anti-amyloids are a promising starting point

By Jane Byrne

The phase 3 trial results for lecanemab and gantenerumab presented at the Clinical Trials on Alzheimer’s Disease (CTAD) conference demonstrate why optimal treatment of Alzheimer’s will require drugs that do more than clear amyloid plaques, says the Alzheimer’s...

Pic:getty/kojofeja

BigHat Biosciences enters AI research collaboration with Merck

By Rachel Arthur

BigHat Biosciences, a US biotech with a machine learning-guided antibody discovery and development platform, has announced a collaboration with Merck to apply its technology to design candidates for up to three drug discovery programs.

Pic:getty/morsaimages

Blue Water Vaccines to develop oral chlamydia vaccine

By Rachel Arthur

Blue Water Vaccines has signed an exclusive, global license agreement for the development of a live attenuated, oral Chlamydia vaccine candidate from The University of Texas Health San Antonio.

Pic:getty/dzmitrydzemidovich

Long-COVID personalized medicine enters Phase 2 trial

By Rachel Arthur

GeNeuro has recruited the first patients in a Phase 2 trial evaluating temelimab against long-COVID: assessing the efficacy of the treatment for improving cognitive impairment and fatigue.

© GettyImages/Charday Penn

Oramed inks deal to commercialize oral insulin in South Korea

By Jane Byrne

Oramed Pharmaceuticals, a company focused on the development of oral drug delivery platforms, has signed an exclusive commercial distribution agreement for the Republic of Korea with local player, Medicox Co Ltd, in relation to its oral insulin candidate....

Pic:getty/markrubens

BioNTech acquires GMP manufacturing site in Singapore

By Rachel Arthur

BioNTech will create an mRNA facility in Singapore through the acquisition of a Novartis site: which will become its Regional Headquarters and production center for the Asia Pacific region.

Pic:getty/nicholasfree

EdiGene Biotechnology moves into new R&D center in Massachusetts

By Rachel Arthur

EdiGene Biotechnology USA has moved into a new Research & Development Center in Waltham, Mass. to advance its proprietary LEAPER tech into in vivo RNA editing therapies: with an initial focus on ophthalmology and the central nervous system.

Follow us

Products

View more

Webinars